1. Introduction {#s0005}
===============

In the present study, we design on the strengths of existing research and considered the epidemic model and vaccination game and multi-serotype approaches, which in turn is based on evolutionary game theory and gives rise to the human decision-making process. The theoretical approach pioneered by [@b0005] and others ([@b0010], [@b0015], [@b0020]) played an important role in epidemiology in terms of the control and prevention of contagious diseases. Recently, this area of study has been accentuated due to the advent of a new strain of pandemic diseases such as influenza, smallpox, SARS (severe acute respiratory syndrome), pneumonia, and dengue fever, among others. Precisely, if we are concerned more to control infectious diseases by immunization, pathogens become more robust to survive and developed new antigenic strains ([@b0025], [@b0030]). One such 'enhanced disease' phenomenon is attributed to antibody-dependent enhancement (ADE), which gives rise to a bolstered viral growth rate in a secondary infection following recovery from a primary infection caused by a variety of serovars ([@b0035], [@b0040], [@b0045]) (see [Fig. 1](#f0005){ref-type="fig"} ). Antibody-dependent enhancement represents an evolutionary advancement in multi-strain viruses that makes vaccination difficult. More specifically, this enhancement presents obstacles to optimal immunization that includes all strains of a disease. The reason for this is that newly developed vaccines against only one serotype can increase the possibility of infection by a second serotype. This is particularly risky for people suffering from dengue fever and its related conditions, because infections in this case are particularly severe.Fig. 1Schematic phase diagram of Antibody-Depending Enhancement (ADE) effect for four-serovars dengue disease: DEN 1, DEN 2, DEN 3 and DEN 4. The mechanism of ADE may be perceived when an individual who has previously infected (primary infected) with one serotype of the dengue infected again (secondary infected) months or years later with a different serotype. While an individual is infected with one serotype dengue disease (say DEN 1), the immune response developed antibodies against this particular serotype (DEN 1: green) dengue disease that prevents the virus from binding to macrophage cells. However, if another serotype of dengue virus: DEN 2/DEN 3/DEN 4 (orange/red/blue) infect the same individual, the immune system is misled because the four serotypes have similar surface antigens. The antibodies cannot recognize the surface protein of the newly attacked virus which proceeds to infect individual because it has not been inactivated by antibodies. This phenomenon is defined as Antibody-dependent enhancement (ADE) that creates the contagious disease much more terrible. The primary infected form mostly minor disease whereas the secondary infected is more likely to be associated with dengue hemorrhagic fever. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Among multi-serotypes epidemics, dengue fever, one of the most devastating mosquito-borne viral infections to humans, is a significant problem worldwide ([@b0050], [@b0055]). The disease is caused by infection with any of four virus serotypes: DEN-1, DEN-2, DEN-3, and DEN-4 ([@b0060]). The virus affects more than 3.9 billion people in 128 countries in the tropical and subtropical regions of the world, and 52% of people are at risk in Asian and Latin American countries ([@b0065], [@b0070], [@b0075]). While researchers and drug authorities are currently developing and testing several promising vaccines, one vaccine is currently commercially available for dengue fever ([@b0080], [@b0090]). The world's first dengue vaccine was CYD-TDV (brand name Dengvaxia). Created by Sanofi Pasteur ([@b0080], [@b0085]) it was licensed in 2015 and commercially introduced in selected countries ([@b0095], [@b0100], [@b0105]). Recently, Takeda's vaccine verified protection against virologically confirmed dengue (VCD), and vaccine trials ended ([@b0110]). The current form of all available dengue vaccines (Sanofi Pasteur and Takeda) target individuals previously infected ([@b0110], [@b0115]), and the vaccine aimed at avoiding second infection. However, for those who have not previously been infected, the vaccine is not as effective. Regarding current vaccination and serotype processes linked to dengue fever, the sequence of infection to which an individual is exposed should be considered. Strategies for self-protection from risk will greatly influence whether first and/or second infections occur. In the case of dengue fever, the most efficient protective measure is vaccination. In this context, the so-called *vaccination game* can be an effective approach for modeling such a complex and dynamic system, where epidemiological dynamics in society can be considered alongside the social evolution of individual decision-making for committing to vaccination in view of governmental policy.

The concept of the vaccination game relies on evolutionary game theory (EGT) alongside an epidemiological compartment model. EGT is a powerful framework for modeling the evolution of cooperation in biological and social sciences. It is the prevailing theoretical framework for understanding social and complex epidemic dynamics ([@b0120], [@b0125], [@b0130]). Epidemiology with vaccination as a major issue in the study of evolutionary biology has been widely researched in the past few decades ([@b0135], [@b0140], [@b0145], [@b0150], [@b0155], [@b0160], [@b0165], [@b0170], [@b0175]). More recently, a number of precursors used theoretical models to better understand epidemic dynamics in both local (single epidemic season) and global (repeated seasons) time scales, in order to explore how to control contagious diseases. Among them, notable studies include [@b0180] for indicating a *meta*-population migration model, [@b0185] for the imperfectness of vaccines using both a multi-agent simulation and theoretical approach, [@b0190] for presenting a subsidy model, [@b0195], [@b0200] for the vaccination game approach with heterogeneous network and buzz effect, and Alam et al.'s ([@b0205]) vaccination game model for introducing the secondary effect of a vaccine in repeated seasons. Additionally, [@b0210] established a mathematical model of SVIR at a local time scale by allowing for the effectiveness of imperfect vaccination, whereas, [@b0215] and others ([@b0220], [@b0225]) succeeded in establishing local time evolutionary epidemic models based on the social learning approach. Additionally, [@b0230] studied the theoretical epidemic model by combining both vaccination and a treatment game approach to explain the impact of secondary provisions as a fail-safe effect. Recently, [@b0235] presented the two-strain with two vaccinations game model by tracking repeated seasons.

Based on the literature, within the vaccination game framework, human decision-making and behavior is multi-modally affected by self-interest, vaccination cost, neighbors' attitudes, and vaccination risk. All of these factors may play an important role in decreasing the risk for both vaccinated and non-vaccinated (free rider) individuals. However, all of the research noted above involving the vaccination game approach presumed vaccination as pre-emptive and lasting only one season. More importantly, the research adopted vaccines that were primarily aimed at treating influenza-like diseases. In the present study, we created a novel realistic model for the vaccination game approach for dengue-like disease treatment by taking into account ADE, where two vaccinations are introduced within a time sequence. Here, primary vaccination should be applied prior to initial infection, with the secondary vaccine following the first infection. Furthermore, spreading of the disease and updating the treatment strategy should be restructured using the same time scale, and the immunity lasts until it wanes.

The main goal of this work is to provide a benchmark for allowing the study of an epidemiological model for dengue transmission once vaccination has been affected. In doing so, the study focuses on representing the effect of ADE and *n*-serovar aspects within the evolutionary game framework. The two types of vaccinations, primary and secondary, were based on the respective dynamics of vaccination rate among individuals, which is affected by individual perceptions of both infection risk and cost burden. The model further allowed for investigating the relationship between ADE, serotypes, and cost-efficiency and how these might influence a vaccine within an evolutionary framework context.

The paper is ordered as follows. First, we formulate our model in detail. This is followed by introducing an evolutionary mechanism for the strategy-updating rule, i.e., modified replicator dynamics. After describing the model, we present simulation results and discuss their implications. Finally, we conclude the paper with a brief discussion of major findings in the conclusion section.

2. Model setup {#s0010}
==============

A modified SVIRS epidemic model in which primary and secondary vaccinations took place is proposed herein to study the influence of primary and secondary infection incidence (due to serotype). Based on the actual ADE mechanism of 4-serovars dengue disease presenting in [Fig. 1](#f0005){ref-type="fig"}, the proposed epidemic model assumed *infection*, *vaccination*, and *recovered* as primary and secondary states. The details of how an individual would ensue for four serotypes is shown in [Fig. 2](#f0010){ref-type="fig"} (A). The model adopted a two-phase (epidemic and evolutionary) model to include an infinite and diverse population ([Fig. 2](#f0010){ref-type="fig"}(B)). It was presumed that an individual could choose whether to have the primary vaccine administered before primary infection and that the same choice was available for commitment to a secondary vaccination once primary recovery was complete but secondary infection had not yet occurred. Individual decisions arise from the evolution of expected payoff and whether a committing provision (primary or secondary vaccination) is perceived as beneficial. We assumed that a primary recovered state from initial infection with any one serotype provided natural life-long immunity against said serotype but led to the enhancement of other serotypes upon secondary infection. Under these circumstances, the total population was divided into seven states: susceptible$(S)$, primary vaccinated $(V^{p})$, primary infected $(I^{p})$, primary recovered $(R^{p})$, secondary vaccinated $(V^{s})$, secondary infected $(I^{s})$, and secondary recovered $(R^{s})$. The set of dynamic equations presented in this work considered the mean field approximation method alongside a compartmental model. Here, *S* represents susceptible individuals (not yet infected), $I_{i}^{p}$ and $R_{i}^{p}$ denotes the fractions of primary infected and primary recovered individuals with $i$ serotypes, respectively, $I_{\mathit{ij}}^{s}$ represents the fraction of secondary infected individuals with $j$ serotypes already recovered from serotype $i$, and $R^{s}$ is the fraction of secondary recovered individuals defined as being in a final recovered state. Meanwhile, $V^{p}$ and $V^{s}$ are the fractions of primary and secondary vaccinated individuals from a susceptible and primary recovered state, specified by variables $x$ and $y$, respectively, and defined as the incidental rate of vaccinators. The fraction of individuals in $V^{p},V^{s},$ and $R^{s}$ decayed, respectively, since such an immunized state does not continue in perpetuity but returns to the susceptible state at the rate of $\alpha$. Furthermore, $\beta_{i},\sigma_{p},$ and $\sigma_{s}$ represent infection rate ($i$ serotype), primary recovery rate, and secondary recovery rate, respectively. The efficiency of vaccines is given as $\eta_{p}{(0 \leq \eta_{p} \leq 1)}$ and $\eta_{s}{(0 \leq \eta_{s} \leq 1)}$, referring to the probability of immunity serving to avoid infection, despite receiving both primary and secondary vaccines. Regarding the schematic diagram in [Fig. 2](#f0010){ref-type="fig"}, the SVIRS model was designed as per the system of differential equations given below:$$\overset{˙}{S} = - \left( {1 - x} \right)S\sum_{i = 1}^{n}\psi_{i} - xS + \alpha V^{p} + \alpha V^{s} + \alpha R,$$ $${\overset{˙}{V}}^{p} = xS - \left( {1 - \eta_{p}} \right)V^{p}\sum_{i = 1}^{n}\psi_{i},$$ $${\overset{˙}{I}}_{i}^{p} = \left( {1 - x} \right)S\psi_{i} + V^{p}\left( {1 - \eta_{p}} \right)\psi_{i} - \sigma_{p}I_{i}^{p},$$ $${\overset{˙}{R}}_{i}^{p} = \sigma_{p}I_{i}^{p} - R_{i}^{p}\sum_{j \neq i}\psi_{j} - \mathit{yR}_{i}^{p},$$ $${\overset{˙}{V}}^{s} = y\sum_{i = 1}^{n}R_{i}^{p} - V^{s}\left( {1 - \eta_{s}} \right)\sum_{i = 1}^{n}\sum_{j \neq i}\psi_{j},$$ $${\overset{˙}{I}}_{\mathit{ij}}^{s} = R_{i}^{p}\psi_{j} - \sigma_{s}I_{\mathit{ij}}^{s} + V^{s}\left( {1 - \eta_{s}} \right)\psi_{j},$$ $${\overset{˙}{R}}^{s} = \sigma_{s}\sum_{i = 1}^{n}\sum_{j \neq i}I_{\mathit{ij}}^{s} - \alpha R^{s}.$$ Fig. 2Schematic image of (A) the transfer chart for S-4 $(n = 4)$ diseases and (B) the entire dynamic model. Relevant parameters are: (i) the probability that susceptible individuals will become infected, ${(1 - x)}\psi_{i}$; (ii) the probability that susceptible people will receive primary vaccination, $x$; (iii) the probability that a primary infected individual will recover, $\sigma_{p}$; (iv) the probability that a primary recovered individual will again be infected, $\psi_{\mathit{ij}}$, due to the effect of ADE factor $\varphi$; (iv) the probability that primary recovered people will be vaccinated, $y$; (v) the probability that secondary infected people will recover, $\sigma_{s}$; (vi) the probability that vaccinated individuals will be infected due to the imperfectness of a vaccine ${(1 - \eta_{p})}\psi_{i}$ in the case of primary and ${(1 - \eta_{s})}\psi_{i}$ secondary vaccinations.

Referring to selected precursors ([@b0035], [@b0040], [@b0045]) as a guideline, we introduce force of infection for $n$ serotypes, $\psi_{i}{(i = 1,2,\cdots n)}$, defined as the ADE factor, where $\varphi_{\mathit{ji}}{( > 1)}$ is given by:$$\psi_{i} = \beta_{i}\left( {I_{i}^{p} + \sum_{j \neq i}\varphi_{\mathit{ji}}I_{\mathit{ji}}^{s}} \right)$$

As a general assumption, we analyzed the symmetric case defined by the setting of various contact rates and ADE factors of all serotypes, equal to: $\beta_{i} = \beta$, $\sigma_{p} = \sigma_{s}$ and $\varphi_{\mathit{ji}} = \varphi$. A total $n$ primary and $n\left( {n - 1} \right)$ secondary infection groups existed; the possible number of infections an individual could contract was up to $n$ times. Here, we analyzed two cases for $n = 2,$ defined as 2-serovar (hereafter, S-2) and $n = 4,$ defined as 4-serovar (S-4) disease.

3. Dual decision-making processes {#s0015}
=================================

To explore the evolutionary trail arising from human decision-making processes related to vaccination uptake as a rational choice, we considered a modified replicator dynamic by referring to existing studies ([@b0210], [@b0215]). In this context, individuals attempted to change their strategies using a probability proportional to the expected gain or loss of payoff. For the current context, in the evolutionary process, people incorporated two types of decision-making processes: primary and secondary vaccination. Here, an individual can become vaccinated against being susceptible to primary infection and receive secondary vaccination following primary recovery. The payoff in both instances depends on the difference between (a) the penalty of risking infection and (b) the drawbacks of being vaccinated. The drawback of the vaccine for primary and secondary vaccination can be quantified as $C_{p}V^{p}$ and $C_{s}V^{s}$, and the penalty of being infected due to primary and secondary infection can be evaluated as $I_{\mathit{total}}^{p}$ and $I_{\mathit{total}}^{s}$. This was derived from the premise that the relative expected cost of primary (secondary) vaccination was $C_{p}\left( C_{s} \right) = C_{v}/C_{i}$, where $C_{v}$ is the vaccination cost and $C_{i}$ is infection cost (here, $C_{i}{= 1)}$. Consequently, the expression $- C_{p}V^{p} + I_{\mathit{total}}^{p}$ and $- C_{s}V^{s} + I_{\mathit{total}}^{s}$ quantifies the expected payoff gain for changing strategies and its sign controls whether the vaccination or non-vaccination option is preferred. The global dynamics of $x$ and $y$ can be depicted as follows:$$\overset{˙}{x} = mx\left( {1 - x} \right)\left( {- C_{p}V^{p} + I_{\mathit{total}}^{p}} \right),$$ $$\overset{˙}{y} = my\left( {1 - y} \right)\left( {- C_{s}V^{s} + I_{\mathit{total}}^{s}} \right),$$where $x(t)$ is the rate observed at time $t$ at which susceptible individuals become primarily vaccinated, and $y(t)$ is the rate at which primary (temporal) recovered individuals become secondarily vaccinated. Furthermore, $m$ is the proportionality constant that alter the fraction of population into the transferring rate; throughout this study, we assumed$m = 0.03$.

The numerical simulation will be carried out for the stated equations (1--10) of the epidemic model by using the explicit finite difference method. Initially, we presumed the initial conditions for all simulations as, $S\left( 0 \right) \approx 1,V^{p}\left( 0 \right) = V^{s}\left( 0 \right) = R^{p}\left( 0 \right) = R^{s}\left( 0 \right) = I^{S}\left( 0 \right) = 0$ and $I^{p}\left( 0 \right) = 0.00001$. We also assumed that the initial incidental rate of vaccinators to be $x\left( 0 \right) \approx 0{(0.00001)}$ and $y\left( 0 \right) \approx 0{(0.00001)}$.

4. Results and discussion {#s0020}
=========================

In this study, we investigated the diffusion of multi-serotype diseases based on the SVIRS epidemic model and the evolutionary game approach, where two vaccines were disseminated within a population. The stability of the model was reviewed by plotting timeline graphs based on the endemic equilibrium shown in [Fig. 3](#f0015){ref-type="fig"} for the S-2 (solid line) and S-4 (dotted line) diseases. Panels A, B, C, D, E, F, and G, respectively, represent the portion of individuals for the following: susceptible, primary infection $(\sum_{i = 1}^{n}I_{i}^{p})$, secondary infection $(\sum_{j = 1}^{n}\sum_{i \neq j}I_{\mathit{ij}}^{s})$, primary vaccination ($V^{p}$), secondary vaccination ($V^{s}$), primary recovered $\left( {\sum_{i = 1}^{n}R_{i}^{p}} \right),$ and secondary recovered ($R^{s}$). Moreover, we considered two combination of efficiency-cost cases $(\eta,C_{r})$ as follows: $(0.1,0.9)$ for a less efficient and costly vaccine (blue) and $(0.9,0.1)$ for a highly efficient and cheaper vaccine (red), where $\eta = \eta_{p} = \eta_{s}$ and $C_{r} = C_{p} = C_{s}$. For comparison, we included a case without vaccination (black). The numerical simulations were conducted using the following model parameter values: $\beta = 0.4$ and $\varphi = 2.0$, where $\beta = \beta_{i}$ and $\varphi = \varphi_{\mathit{ij}}.$ Throughout the numerical results provided below, we fixed $\sigma = 0.1(\sigma = \sigma_{p} = \sigma_{s})$ and $\alpha = 0.008$.Fig. 3Dynamic behavior of a system comprising S-2 and S-4 diseases with $\beta = 0.4,\sigma = 0.1,\varphi = 2.0,\alpha = 0.008,$and $\left( {\eta,C_{r}} \right) = {({0.1,0.9})}$ (blue), $\left( {\eta,C_{r}} \right) = {({0.9,0.1})}$ (red), and without vaccination (gray). Time series of (A) susceptible, (B) primary infection, (C) secondary infection, (D) primary vaccination, (E) secondary vaccination, (F) primary recovered, and (G) secondary recovered. Here, $\eta = \eta_{p} = \eta_{s}$, $C_{r} = C_{p} = C_{s}$, $\beta = \beta_{i}$, $\sigma = \sigma_{p} = \sigma_{s}$, and $\varphi = \varphi_{\mathit{ij}}$. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Comparing S-2 with S-4 diseases, we observed an increase in serotype diversity causing a subsequent rise in disease incidence (panels B and C). A similar tendency was also observed in the case of both vaccinated and secondary recovered individuals (panels D, E, and G). Enhancement of serotype diversity increased the portion of both vaccinated and secondary recovered groups. However, only one exception was observed for the primary recovered (panel F) group, suggesting that an increase in serotype diminished the portion of recovered individuals. This can be fully justified by the fact that a higher number of disease serotypes intensified the transmission from primary recovered to secondary infection. Additionally, [Fig. 3](#f0015){ref-type="fig"} highlights that the impact of both vaccinations (primary and secondary) suppressed the spread of the disease when compared with non-vaccination or the default settings (no vaccination and evolutionary mechanism taking place). Furthermore, it appears that a higher efficiency at a cheaper cost delivered higher vaccination uptake, which in turn reduced infection for both primary and secondary incidences. The opposite tendency was observed in the case of less efficient and more expensive vaccines. According to results in general, even though more individuals will benefit from either primary or secondary vaccination, an epidemic cannot be eradicated by these two vaccination types as employed in the parameter settings noted here.

The discussion above nonetheless indicates that the model was successful, indicating an appropriate dynamic that is to some degree able to achieve a state of equilibrium. Thus, in the following discussion, we focus on the results observed at equilibrium for a variety of model parameters.

In order to derive an insightful understanding of how ADE factors and disease transmission function for two different serotypes (S-2 and S-4), we present a two-dimensional (2D) heat map of primary infected, secondary infected, primary vaccinated, and secondary vaccinated groups in [Figs. 4](#f0020){ref-type="fig"} (a), (b) and [5](#f0025){ref-type="fig"} (a), (b), respectively. In each figure, panel A and panel B display the S-2 and S-4 disease for two vaccine efficiencies $\left( {\eta_{p},\eta_{s}} \right)$ as (\*-i) $\left( {0.1,0.1} \right)$, (\*-ii) $\left( {0.1,0.9} \right)$, (\*-iii) $\left( {0.9,0.1} \right),$ and (\*-iv) $\left( {0.9,0.9} \right)$ and for their corresponding costs $\left( {C_{p},C_{s}} \right)$ as (a-\*) $\left( {0.0,0.0} \right)$, (b-\*), $\left( {0.0,1.0} \right)$, (c-\*) $\left( {1.0,0.0} \right),$ and (d-\*) $\left( {1.0,1.0} \right),respectively$. Each sub-panel provides a 2D phase plane for the ADE factor, i.e., $\varphi(1 \leq \varphi \leq 3)$ and for infection rate, i.e., $\beta(0 \leq \beta \leq 1)$. Throughout, we can see from [Fig. 4](#f0020){ref-type="fig"} that the fraction of infected individuals increased as ADE factor $\varphi$ increased. Since ADE factor defined quantifying enhancement of synergetic contact in the secondary infection rate, it was expected to play a significant role in increasing disease outbreaks. Meanwhile, it was observed that the outcome exhibited two equilibrium points, a disease-free state $R_{0} < 1$ and an endemic state $R_{0} > 1$, where $R_{0}$ was the basic reproduction number defined as $R_{0} = \beta/\sigma$ and, as already noted, we fixed $\sigma = 0.1$. Accordingly, the disease will regress if $\beta < 0.1\left( {R_{0} < 1} \right),as$ presented by the deep blue region of [Fig. 4](#f0020){ref-type="fig"}, that also brings no vaccination area ([Fig. 5](#f0025){ref-type="fig"}). Another aspect that may also affect the fraction of both primary and secondary infected individuals is relevant vaccines cost $C_{p}{(C_{s})}$ and their efficiency being $\eta_{p}{(\eta_{s})}$. From this result, three primary factors were observed, as discussed below.Fig. 4(a): Phase diagrams of primary infection individuals along infection rate $\beta$ and ADE factor $\varphi$. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost $(C_{p},C_{s})$ as (a-\*) $({0.0,0.0})$, (b-\*) $({0.0,1.0})$, (c-\*) $\left( {1.0,0.0} \right),$ and (d-\*) $\left( {1.0,1.0} \right),$ and the outcome of variable efficiency $(\eta_{p},\eta_{s})$ as (\*-i) $({0.1,0.1})$, (\*-ii) $({0.1,0.9})$, (\*-iii) $\left( {0.9,0.1} \right),$ and (\*-v) $({0.9,0.9})$. Additional parameters are $\beta = 0.4$ and $\sigma = 0.1$. (b): Phase diagrams of secondary infection individuals along infection rate $\beta$ and ADE factor $\varphi$. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost $(C_{p},C_{s})$ as (a-\*) $({0.0,0.0})$, (b-\*) $({0.0,1.0})$, (c-\*) $\left( {1.0,0.0} \right),$ and (d-\*) $({1.0,1.0})$, and the outcome of varying efficiency $(\eta_{p},\eta_{s})$ as (\*-i) $({0.1,0.1})$, (\*-ii) $({0.1,0.9})$, (\*-iii) $\left( {0.9,0.1} \right),$ and (\*-v) $({0.9,0.9})$. The remaining parameters are $\beta = 0.4$ and $\sigma = 0.1$.Fig. 5(a): Phase diagrams for primary vaccination individuals along infection rate $\beta$ and ADE factor $\varphi$. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost $(C_{p},C_{s})$ as (a-\*) $({0.0,0.0})$, (b-\*) $({0.0,1.0})$, (c-\*) $\left( {1.0,0.0} \right),$ and (d-\*) $\left( {1.0,1.0} \right),$ and the outcome of varying efficiency $(\eta_{p},\eta_{s})$ as (\*-i) $({0.1,0.1})$, (\*-ii) $({0.1,0.9})$, (\*-iii) $\left( {0.9,0.1} \right),$ and (\*-v) $({0.9,0.9})$. The remaining parameters are $\beta = 0.4$ and $\sigma = 0.1$. (b): Phase diagrams of secondary vaccination individuals along infection rate $\beta$ and ADE factor $\varphi$. Panels A and B present S-2 and S-4 diseases, respectively. Each panel shows the result of varying vaccination cost $(C_{p},C_{s})$ as (a-\*) $({0.0,0.0})$, (b-\*) $({0.0,1.0})$, (c-\*) $\left( {1.0,0.0} \right),$ and (d-\*) $\left( {1.0,1.0} \right),$ and the outcome of varying efficiency $(\eta_{p},\eta_{s})$ as (\*-i) $({0.1,0.1})$, (\*-ii) $({0.1,0.9})$, (\*-iii) $\left( {0.9,0.1} \right),$ and (\*-v) $({0.9,0.9})$. The remaining parameters are $\beta = 0.4$ and $\sigma = 0.1$.

First, the higher efficiency and lower cost for primary vaccination (sub-panels (a-iii), (a-iv), (b-iii), and (b-iv)) encouraged people to receive primary vaccination ([Fig. 5](#f0025){ref-type="fig"}(a)), which naturally led to a lower rate of primary infection ([Fig. 4](#f0020){ref-type="fig"}(a)).

Second, for one of the four combinations above (sub-panel (a-iv)), higher efficiency and lower cost were implemented not only for the first but also secondary vaccinations, the results indicating a lower rate of secondary vaccination ([Fig. 5](#f0025){ref-type="fig"}(b) (a-iv)). Therefore, we can state that this particular tendency is not uncommon but likely, since there were fewer people who were infected in the secondary infection group ([Fig. 4](#f0020){ref-type="fig"}(b) (a-iv)). These results indicate that primary vaccination worked effectively and so many people taking the primary immunization policy. As a result, there was no need to receive secondary vaccination.

Third, and similar to the first point, the higher efficiency and lower cost of the secondary vaccination (sub-panels (a-ii), (c-ii), and (c-iv)) encouraged people to commit to receiving secondary vaccination ([Fig. 5](#f0025){ref-type="fig"}(b)), which reduced the size of secondary infection ([Fig. 4](#f0020){ref-type="fig"}(b)). Although the case of (a-iv) should be one of above those, it does not indicate a high fraction of secondary vaccination. The reason why this happens was what we already discussed in the previous paragraph.

Visually comparing the S-2 and S-4 cases (as per comparison of panel A and panel B in [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}), shows the outcome likewise, where S-4 cases demonstrated relatively higher infectious situations but a smaller vaccinated region.

To establish appropriate provisions within society for exploring effective financial support policy (e.g., subsidy, discounts, or free-tickets) to control the spread of disease, we present another 2D heat map in [Fig. 6](#f0030){ref-type="fig"} . The figure indicates secondarily infected (S-4) individuals ($\sum_{j = 1}^{n}\sum_{i \neq j}I_{\mathit{ij}}^{s}$) along with primary vaccine efficiency $\eta_{p}$ and secondary vaccine efficiency $\eta_{s}$. In the case of dengue fever, a portion of secondary infected individuals will be exposed to danger of death; research is needed to effectively reduce this number. Here, sub-panels (a-\*), (b-\*), and (c-\*) indicate preferences for primary vaccination $(C_{p} = 0.1,C_{s} = 0.5)$, the default setting $(C_{p} = 0.5,C_{s} = 0.5)$, and a preference for secondary vaccination $(C_{p} = 0.5,C_{s} = 0.1)$. As a reference, sub-panel (d-\*) indicates preference for both vaccinations $(C_{p} = 0.1,C_{s} = 0.1)$. Here, we used the term 'preference' to imply the specific vaccination that the public health authority prioritized. For example, 'preference of primary vaccination' implies that governmental subsidy for encouraging primary vaccination (cheaper cost; *C~p~* can be derived vis-a-vis the default case) exists. Additionally, sub-panels (\*-i), (\*-ii), and (\*-iii) present the variation of infection rates for $\beta = 0.2$ ($R_{0} = 2$), $0.4$ ($R_{0} = 4$), and 0.8 ($R_{0} = 8$).Fig. 6Phase diagram for secondary infection individuals with S-4 along primary efficiency $\eta_{p}$ and secondary efficiency $\eta_{s}$. The preference for primary vaccination as $(C_{p} = 0.1,C_{s} = 0.5)$, default case as $(C_{p} = 0.5,C_{s} = 0.5)$, preference for secondary vaccination as $\left( {C_{p} = 0.5,C_{s} = 0.1} \right),$ and preference for both vaccinations as $(C_{p} = 0.1,C_{s} = 0.1)$ are presented in sub-panels (a-\*), (b-\*), (c-\*), and (d-\*), respectively. Here, the infection rate is varied as (\*-i) $\beta = 0.2$, (\*-ii) $\beta = 0.4,$ and (\*-iii) $\beta = 0.8$. The remaining parameters are $\varphi = 2.0$ and $\sigma = 0.1$.

Deliberately observing all panels, we observed that the width of the blue region (from light to deep blue) shown in the Y-axis (extending in the $\eta_{p}$-direction) was wider than in the X-axis (extending in the $\eta_{s}$-direction); however, the extent of the blue color in the X-axis region was darker than in the Y-axis. This tendency was more evidently observed in the dotted box of panel (d--i) (presuming weaker infection rate and a preference for both vaccination types). This tendency can also be observed in other parameter settings.

The above observation implies the following. To suppress secondary infection, secondary vaccination requires high efficiency (reliability). However, if a higher $\eta_{s}$ can be realized, the effect will become significant. Contrastingly, the primary vaccination, despite not having higher efficiency for $\eta_{p}$ will still work reasonably effective in terms of suppressing secondary infection. This can be attributed to the secondary vaccination being introduced at a more downstream point within the process of infection dynamics, as shown in [Fig. 2](#f0010){ref-type="fig"}, compared to where primary vaccination is situated. Thus, a much more drastic effect is needed to subdue the spread of secondary infection. However, once this has been established, the impact of secondary vaccination will be significant.

The next step is to provide analogous phase diagrams for secondary infected (\*-i), susceptible (\*-ii), primary vaccinated (\*-iii), and secondary vaccinated (\*-iv) individuals against a S-4 according to variable infection rates (a-\*) $\beta = 0.2$, (b-\*) $\beta = 0.4,$ and (c-\*) $\beta = 0.8$ (see [Fig. 7](#f0035){ref-type="fig"} ). In doing so, the assumption of a low-cost vaccine is made for both costs $(C_{p} = C_{s} = 0.1)$ introduced above, in a case where both vaccinations are equally emphasized by the public health authority. It is worth noting that the dotted triangles for the weaker infection rate ($\beta = 0.2$) display higher susceptibility but lower secondary infection, despite relatively lower coverage for both vaccinations. Referring to existing studies ([@b0125], [@b0130], [@b0135]), this indicates that 'free-riding' on the so-called 'herd immunity' does occur, as a high efficiency for both vaccinations and relatively weaker infection rate only requires limited vaccination coverage within a society in order to stop the disease from spreading. This allows for a reasonable percentage of free-riders (no vaccination) to be present in the society.Fig. 7Full phase diagrams of (\*-i) secondary infection (\*-ii), susceptible (\*-iii), primary vaccination, and (\*-iv) secondary vaccination individuals for S-4 disease along primary efficiency $\eta_{p}$ and secondary efficiency $\eta_{s}$. Here, the infection rate is varied as (\*-i) $\beta = 0.2$, (\*-ii) $\beta = 0.4,$ and (\*-iii) $\beta = 0.8$. The remaining parameters are $\sigma = 0.1$, $C_{p} = 0.1,C_{s} = 0.1$ and $\varphi = 2.0$.

5. Conclusion {#s0025}
=============

Applying the vaccination game approach to epidemics, we proposed an *n*-serovar SVIRS disease model for studying the effect of ADE for two vaccination types, primary and secondary, as it relates to the control and preclusion of contagious diseases. Model investigations and numerical simulations were carried out by including two voluntary vaccination options with several parameters including vaccination cost, efficiency, and ADE factor for two serotypes (S-2 and S-4). Our model can easily be extended to a generalized *n*-serotype model for arbitrary infections. The model presumed modified replicator dynamics and a mean field approximation, i.e., an infinite and diverse population.

We found an established vaccination policy implemented by health authorities for controlling vaccination efficiency (investment required for improving vaccination efficiency) and the cost to individuals for being vaccinated (subsidies allowing for vaccination) to be crucial to infectious systems in which dual vaccinations are implemented. Additionally, the ADE effect also enhanced contagious disease where infections were involved.

We posited that secondary vaccination should be addressed if its efficiency can be established as being high. Secondary vaccination works at an immediately antecedent stage in the sequence of an infectious process; therefore, irrespective of how effective primary vaccination is, a highly efficient secondary vaccine will be able to minimize death casualties by, among others, dengue fever.

Contrastingly, if a highly efficient secondary vaccination is less conceivable, primary vaccination must take on the burden of stopping the disease from spreading. This implies that an appropriate combination of primary and secondary vaccinations will need to be designed.
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